Atherosclerosis is a chronic disease of the arteries whose development involves a local inflammatory response characterized by the activation of different cells such as macrophages, T-lymphocytes, smooth muscle cells (SMCs) and endothelial cells (ECs). This review will summarize recent evidence for a modulatory role of the nuclear receptor ROR-α in cardiovascular disease.
References
1.
AssmannG., SchulteH., FunkeH., and von EckardsteinA. (1998). The emergence of triglycerides as a significant independent risk factor in coronary artery diseaseEur Heart J19 Suppl M, M8–14.
2.
AtkinsG. B., HuX., GuentherM. G., RachezC., FreedmanL. P., and LazarM. A. (1999). Coactivators for the orphan nuclear receptor RORalphaMol Endocrinol13, 1550–7.
3.
BesnardS., HeymesC., MervalR., RodriguezM., GalizziJ. P., BoutinJ. A., MarianiJ., and TedguiA. (2002). Expression and regulation of the nuclear receptor RORalpha in human vascular cellsFEBS Lett511, 36–40.
4.
BesnardS., SilvestreJ. S., DuriezM., BakoucheJ., Lemaigre-DubreuilY., MarianiJ., LevyB. I., and TedguiA. (2001). Increased ischemia-induced angiogenesis in the staggerer mouse, a mutant of the nuclear receptor RoralphaCirc Res89, 1209–15.
5.
BlakeG. J., and RidkerP. M. (2003). C-reactive protein and other inflammatory risk markers in acute coronary syndromesJ Am Coll Cardiol41, 37S–42S.
6.
CarmelietP. (2000). Mechanisms of angiogenesis and arteriogenesisNat Med6, 389–95.
7.
DeleriveP., MonteD., DuboisG., TrotteinF., Fruchart-NajibJ., MarianiJ., FruchartJ. C., and StaelsB. (2001). The orphan nuclear receptor ROR α is a negative regulator of the inflammatory responseEMBO Rep2, 42–8.
8.
GiguereV. (1999). Orphan nuclear receptors: from gene to functionEndocr Rev20, 689–725.
9.
HamiltonB. A., FrankelW. N., KerrebrockA. W., HawkinsT. L., FitzHughW., KusumiK., RussellL. B., MuellerK. L., van BerkelV., and BirrenB. W. (1996). Disruption of the nuclear hormone receptor RORalpha in staggerer miceNature379, 736–9.
10.
HardingH. P., AtkinsG. B., JaffeA. B., SeoW. J., and LazarM. A. (1997). Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar developmentMol Endocrinol11, 1737–46.
11.
HerrupK., and MullenR. J. (1979). Regional variation and absence of large neurons in the cerebellum of the staggerer mouseBrain Res172, 1–12.
12.
JettenA. M., KurebayashiS., and UedaE. (2001). The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processesProg Nucleic Acid Res Mol Biol69, 205–47.
13.
KallenJ. A., SchlaeppiJ. M., BitschF., GeisseS., GeiserM., DelhonI., and FournierB. (2002). X-ray structure of the hRORalpha LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalphaStructure (Camb)10, 1697–707.
14.
KaneC. D., and MeansA. R. (2000). Activation of orphan receptor-mediated transcription by Ca(2+)/calmodulin-dependent protein kinase IVEmbo J19, 691–701.
15.
KopmelsB., MarianiJ., Delhaye-BouchaudN., AudibertF., FradeliziD., and WollmanE. E. (1992). Evidence for a hyperexcitability state of staggerer mutant mice macrophagesJ Neurochem58, 192–9.
16.
LauP., BaileyP., DowhanD. H., and MuscatG. E. (1999). Exogenous expression of a dominant negative RORalpha1 vector in muscle cells impairs differentiation: RORalpha1 directly interacts with p300 and myoDNucleic Acids Res27, 411–20.
17.
MamontovaA., Seguret-MaceS., EspositoB., ChanialeC., BoulyM., Delhaye-BouchaudN., LucG., StaelsB., DuvergerN., and MarianiJ. (1998). Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalphaCirculation98, 2738–43.
18.
MissbachM., JagherB., SiggI., NayeriS., CarlbergC., and WiesenbergI. (1996). Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor α with potent antiarthritic activityJ Biol Chem271, 13515–22.
19.
Nacer-CherifH., Bois-JoyeuxB., RousseauG. G., LemaigreF. P., and DananJ. L. (2003). Hepatocyte nuclear factor-6 stimulates transcription of the α-fetoprotein gene and synergizes with the retinoic-acid-receptor-related orphan receptor α-4Biochem J369, 583–91.
20.
RaspeE., DuezH., GervoisP., FievetC., FruchartJ. C., BesnardS., MarianiJ., TedguiA., and StaelsB. (2001). Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalphaJ Biol Chem276, 2865–71.
21.
RaspeE., MautinoG., DuvalC., FontaineC., DuezH., BarbierO., MonteD., FruchartJ., FruchartJ. C., and StaelsB. (2002). Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor αJ Biol Chem277, 49275–81.
22.
RossE. M. (1990). Cellular signalling. Viral hijack of receptorsNature344, 707–8.
23.
SchraderM., DanielssonC., WiesenbergI., and CarlbergC. (1996). Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. They also bind COUP-TF homodimersJ Biol Chem271, 19732–6.
24.
SprecherD. L. (1998). Triglycerides as a risk factor for coronary artery diseaseAm J Cardiol82, 49U–56U; discussion 85U-86U.
25.
SundvoldH., and LienS. (2001). Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORalpha1Biochem Biophys Res Commun287, 383–90.
26.
TrenknerE., and HoffmannM. K. (1986). Defective development of the thymus and immunological abnormalities in the neurological mouse mutation “staggerer”J Neurosci6, 1733–7.
27.
ValenG., YanZ. Q., and HanssonG. K. (2001). Nuclear factor kappa-B and the heartJ Am Coll Cardiol38, 307–14.
28.
Vu-DacN., GervoisP., GrotzingerT., De VosP., SchoonjansK., FruchartJ. C., AuwerxJ., MarianiJ., TedguiA., and StaelsB. (1997). Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalphaJ Biol Chem272, 22401–4.
29.
WiesenbergI., ChiesiM., MissbachM., SpankaC., PignatW., and CarlbergC. (1998). Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608Mol Pharmacol53, 1131–8.
